Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium

HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT _{LIVER CANCER} study, a Phase 1b/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).

Presentation Details:
Date: Friday, January 19, 2024
Time: 12:30 p.m. PST
Location: Moscone West, San Francisco, CA
Session Type: Trials in Progress Poster Session
Abstract Title: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Advanced Hepatocellular Carcinoma
Abstract #: TPS577
Poster Bd #: P6

The REVERT _{LIVER CANCER} trial is currently enrolling HCC patients at top US cancer research institutes and is designed to evaluate TTI-101 across multiple lines of therapy:

• TTI-101 alone for patients previously treated with up to three prior lines of systemic therapy
• TTI-101 in combination with pembrolizumab (Keytruda®) for patients previously treated with immunotherapy
• TTI-101 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for treatment-naïve patients

HCC is the most common form of liver cancer; however, treatment options for the disease are limited and overall prognosis is poor, with a 5-year survival rate of 18%. TTI-101’s target, STAT3, is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment. TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.

“We are excited to present this unique trial design that allows us to evaluate the potential of TTI-101 to enhance outcomes across 1^st, 2^nd, and last line HCC patients, where the current standard of care is insufficient,” said Imran Alibhai, PhD, CEO of Tvardi Therapeutics.

For more information about the REVERT _{LIVER CANCER} trial, please visit ClinicalTrials.gov (NCT05440708).

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company has now initiated three Phase 2 clinical programs in STAT3-driven diseases: hepatocellular carcinoma (NCT05440708), metastatic breast cancer (NCT05384119), and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240118383580/en/